Physician profile
Mark A Milchak
NPI 1225195233
$7,399.79
in general payments reported to CMS, 2019-2025
19 companies · $847 in 2025
The $847 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,348 · 2020: $435 · 2021: $983 · 2022: $987 · 2023: $1,410 · 2024: $1,390 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,642 · Education: $4.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,641.97 |
| Education | $4.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,107.53 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $1,683.69 | 2020-2025 | Farxiga, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $921.70 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $467.26 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $253.21 | 2025 | |
| Amgen INC. | $249.30 | 2019-2025 | Repatha |
| Lantheus Medical Imaging, INC. | $227.24 | 2021-2023 | Definity |
| Boston Scientific Corporation | $221.00 | 2020-2023 | Watchman Access System |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Pfizer INC. | $162.29 | 2019-2021 | |
| Edwards Lifesciences Corporation | $152.06 | 2024-2025 | Sapien 3 Ultra Resilia |
| Heartflow, INC. | $150.64 | 2024-2025 | |
| Atricure, INC. | $142.49 | 2023 | |
| Abiomed | $129.12 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.23 | 2024 | Jardiance |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $103.47 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.72 | 2025 | Lifevest |
| Astellas Pharma US INC | $12.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Milchak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.